Canada-based Appili Therapeutics has enrolled and dosed the first cluster of participants in its Phase II CONTROL COVID-19 clinical trial of favipiravi, developed by FUJIFILM Toyama Chemical. Yourway has a local depot that’s 6,000 square feet conveniently located in Toronto, Canada to better serve the clinical trial needs in the country.